. "Appendix F: Ethical Issues in Immunotherapies and Depot Mechanisms for Substance Abuse." New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: The National Academies Press, 2004.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions
Ad Hoc Committee on Growth Hormone Usage. (1983). Growth hormone in the treatment of children with short stature. Pediatrics,72(6), 891-894.
American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. (1997). Considerations related to the use of recombinant growth hormone in children. Pediatrics,99(1), 122-129.
Angell, M. (2000). Is academic medicine for sale? New England Journal of Medicine,342(20), 1516-1518.
Appelbaum, P.S. (2002). Involving decisionally impaired subjects in research: The need for legislation. American Journal of Geriatric Psychiatry,10(2), 120-124.
Bekelman, J.E., Li, Y., and Gross, C.P. (2003). Scope and impact of financial conflicts of interest in biomedical research: A systematic review. Journal of the American Medical Association,289(4), 454-465.
Benjamin, M., Muyskens, J., and Saenger, P. (1984). Short children, anxious parents: Is growth hormone the answer? Hastings Center Report,14, 5-9.
Bodenheimer, T. (2000). Uneasy alliance—Clinical investigators and the pharmaceutical industry. New England Journal of Medicine,342(20), 1539-1544.
Charland, L.C. (2002). Cynthia’s dilemma: Consenting to heroin prescription. American Journal of Bioethics,2(2), 37-47.
Chen, D.T., Miller, F.G., and Rosenstein, D.L. (2002). Enrolling decisionally impaired adults in clinical research. Medical Care,40(Suppl 9), V20-V29.
Cuttler, L., Silvers, J.B., Singh, J., Marrero, U., Finklestein, B., Tannin, G., and Neuhauser, D. (1996). Short stature and growth hormone therapy: A national study of physician recommendation patterns. Journal of the American Medical Association,276(7), 531-537.
Davis, D.S. (2001). Genetic dilemmas: Reproductive technologies, parental choices, and children’s futures. New York: Routledge.
Dresser, R. (1984). Bound to treatment: The Ulysses contract. Hastings Center Report,14(3), 13-16.
Faden, R.R., Beauchamp, T.L., and King, N.M.P. (1986). A history and theory of informed consent. New York: Oxford University Press.
Feinberg, J. (1980). The child’s right to an open future. In W. Aiken and H. LaFallette (Eds.), Whose child? Children’s rights, parental authority, and state power (pp. 124-153). Totowa, NJ: Littlefield, Adams.
Feussner, J.R., and Murray, T.H. (2002). Making informed consent meaningful: A state-of-the-art conference. Medical Care,40(Suppl 9), V1-V3.
Food and Drug Administration. (2001). Additional safeguards for children in clinical investigations of FDA related products. Federal Register,66(79), 20589-20600.
Holmes-Rovner, M., and Wills, C.E. (2002). Improving informed consent: Insights from behavioral decision research. Medical Care,40(Suppl 9), V30-V38.
Kaplowitz, P.B. (2001). If gonadotropin-releasing hormone plus growth hormone (GH) really improves growth outcomes in short non-GH-deficient children, then what? Journal of Clinical Endocrinology and Metabolism,86(7), 2965-2968.
Klerman, G.L. (1972). Psychotropic hedonism vs. pharmacological Calvinism. Hastings Center Report,2(4), 1-3.
Kopelman, L.M. (2000). Children as research subjects: A dilemma. Journal of Medicine and Philosophy,25(6), 745-764.
Lawson Wilkins Pediatric Endocrine Society. (1995). Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Journal of Pediatricss,127(6), 857-867.